LO FRANCIS sold $2.2M of ADPT
LO FRANCIS (Chief People Officer) sold 95,842 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $22.51 ($22.18–$22.59, $2.16M total) across 3 trades over 2026-07-01 to 2026-07-02 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific sale size, price range, and that it was executed under a pre-arranged Rule 10b5-1 plan; this typically reduces the informational content versus discretionary selling.
Market read
Traders may monitor for follow-on insider activity, but this filing alone is unlikely to drive a durable repricing.
What to watch
The disclosure does not state tax, diversification, or liquidity needs; without those details, interpreting directionality for fundamentals is unreliable.
Background
The article is an SEC Form 4 insider transaction for Adaptive Biotechnologies’ Chief People Officer, reported via SEC EDGAR.
Ticker impact
Adaptive Biotechnologies insider Lo Francis sold 95,842 shares in open-market trades at $22.18–$22.59 per share under a 10b5-1 plan.
Likely limited near-term impact; any effect should be small and sentiment-driven rather than fundamental.
The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan, and it provides sale pricing/size without any accompanying operational or guidance change.
Market effects
Minimal—single-company insider sale under 10b5-1 does not signal sector-wide change.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still be read by some traders as a mild negative signal about near-term risk/reward.
Key entities
- issuerAdaptive Biotechnologies Corp
Subject of the Form 4 insider sale disclosure.
- insiderLo Francis
Chief People Officer who sold shares in open-market trades.
